Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20670548 | 0.88 | OPRK1 (0.54) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL20670475 | 0.88 | OPRM1 (0.58) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL20670779 | 0.86 | OPRK1 (0.47) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL24611001 | 0.83 | OPRK1 (0.42) | OPRM1OPRK1 | |
| SCHEMBL20670670 | 0.78 | OPRM1 (0.50) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL22985993 | 0.78 | OPRK1 (0.44) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL20670883 | 0.77 | OPRM1 (0.55) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL20500041 | 0.76 | OPRK1 (0.53) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL22985986 | 0.75 | OPRK1 (0.56) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL20499954 | 0.75 | OPRM1 (0.49) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596069-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-10676469-B2 | Kappa opioid receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190023700-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRK1 1/4885OPRD1 2/4885 |
| US-20190023700-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRK1 1/4885OPRD1 2/4885 |
| US-10676469-B2 | Kappa opioid receptor antagonists and products and methods related thereto | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRK1 1/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.